A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)

What is this summary about? This summary describes early (not final) results of a clinical study called CHOICE-01. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy (chemicals used to stop the growth of or kill cancer cells) for adults with untreated non-small cell lung cancer (NSCLC) without driver mutations (i.e. EGFR/ALK mutations excluded from the study) that was classified as locally advanced or had spread to other parts of the body (metastatic NSCLC). Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time adults with untreated advanced NSCLC not suitable for surgery could live without their cancer getting worse (a measurement called ‘progression-free survival’), and living longer (a measurement called “overall survival”). What are the key takeaways? Results from the CHOICE-01 study showed that adults with advanced inoperable NSCLC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. Early results for overall survival, a measurement of how long patients lived overall, also demonstrated significantly better results in the group treated with toripalimab. The treatment groups with and without toripalimab had similar rates of side effects (effects of a medicine that are beyond its desired effect that can be harmful), which were tracked to assess safety. What were the main conclusions reported by the researchers? The results of the CHOICE-01 study showed that patients with advanced NSCLC treated with toripalimab plus chemotherapy had longer progression-free survival and overall survival than those who received chemotherapy alone. These results support the addition of toripalimab to chemotherapy for adults with untreated advanced NSCLC without driver mutations. Who is this summary for? This summary is intended to provide information to adults with advanced NSCLC and their family members or caregivers. It may also be helpful for patient advocates and healthcare professionals.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-12-04
DOI
https://doi.org/10.1080/14796694.2024.2426951
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)

Xinmei Yang, Shaozhang Zhou, Hui Feng, Bo Zhu et al.
1 links
Future Oncology
Lung Cancer Treatments and Mutations
article

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)

Xinmei Yang, Shaozhang Zhou, Hui Feng, Bo Zhu, Shi Jin, Hui Zhao, Youxin Ji, Diansheng Zhong, Yu Yao, Jian Feng, Buhai Wang, Qiming Wang, Y.-P. Liu, Jiuwei Cui, Xiaohong Wu, Jianjin Huang, Ying Cheng, Tong Zhou, Xiongwen Tang, Sheng Yao, Dongqing Lv, Yuming Jia, Jianxin Gu, Dong Wang, Anwen Liu, Sheng Hu, Liyun Miao, Guogui Sun, Yongqian Shu, Patricia Keegan, Qisen Guo, Lin Wu, Yingyi Wang, Mei He, Wei Zhang, Xiaoling Li, Hu Liu, Zhijie Wang, Zhihong Zhang, Qiang Li, Yong Song, Zhuang Yu, Lei Nie, Yan Yu, Baohui Han, Cheng Huang, Yun Fan, Meiqi Shi, Jianhua Shi, Xiuwen Wang, Caicun Zhou, Mei Ji, Xiaoli Zhu, Zhenzhou Yang, Zhigang Han, Baolan Li, Ziping Wang, Xicheng Wang, Xingya Li, Jun Yang, Jingxun Wu, Jianjun Yu, Xiaodong Zhang, Beili Gao, Ellen Maher, Liang Han, Jie Wang
article en

Abstract

What is this summary about? This summary describes early (not final) results of a clinical study called CHOICE-01. The study looked at the effect of a medicine called toripalimab when added to standard chemotherapy (chemicals used to stop the growth of or kill cancer cells) for adults with untreated non-small cell lung cancer (NSCLC) without driver mutations (i.e. EGFR/ALK mutations excluded from the study) that was classified as locally advanced or had spread to other parts of the body (metastatic NSCLC). Researchers wanted to see whether toripalimab added to standard chemotherapy was safe and effective for increasing the amount of time adults with untreated advanced NSCLC not suitable for surgery could live without their cancer getting worse (a measurement called ‘progression-free survival’), and living longer (a measurement called “overall survival”). What are the key takeaways? Results from the CHOICE-01 study showed that adults with advanced inoperable NSCLC treated with toripalimab plus standard chemotherapy had significantly longer progression-free survival than those who received standard chemotherapy alone. Early results for overall survival, a measurement of how long patients lived overall, also demonstrated significantly better results in the group treated with toripalimab. The treatment groups with and without toripalimab had similar rates of side effects (effects of a medicine that are beyond its desired effect that can be harmful), which were tracked to assess safety. What were the main conclusions reported by the researchers? The results of the CHOICE-01 study showed that patients with advanced NSCLC treated with toripalimab plus chemotherapy had longer progression-free survival and overall survival than those who received chemotherapy alone. These results support the addition of toripalimab to chemotherapy for adults with untreated advanced NSCLC without driver mutations. Who is this summary for? This summary is intended to provide information to adults with advanced NSCLC and their family members or caregivers. It may also be helpful for patient advocates and healthcare professionals.

Future OncologyVol. 21(5)
Qingdao University (CN), Jiangnan University (CN), Central South University (CN), Capital University (US), Nanchang University (CN), Army Medical University (CN), Xinjiang Medical University (CN), Harbin Medical University (CN), Chongqing University (CN), Shanxi Medical University (CN), Capital Medical University (CN), Guangdong Pharmaceutical University (CN), Dalian Medical University (CN), Jilin University (CN), Anhui Medical University (CN), Nantong University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Wenzhou Medical University (CN), Nanjing General Hospital of Nanjing Military Command (CN), Peking Union Medical College Hospital (CN), Ruijin Hospital (CN), Tianjin Medical University General Hospital (CN), Shanghai Chest Hospital (CN), Affiliated Hospital of Nantong University (CN), First Affiliated Hospital of Xiamen University (CN), National Cancer Center (US), Bioscience (China) (CN), Second Affiliated Hospital of Guangzhou Medical University (CN), Daping Hospital (CN), Peking University Cancer Hospital (CN), Second Affiliated Hospital of Chongqing Medical University (CN), Tangshan People's Hospital (CN), Jilin Province Tumor Hospital (CN), BioReliance (United States) (US), Tumor Hospital of Xinjiang Medical University (CN), Shanxi Provincial Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Nantong Tumor Hospital (CN), The First People's Hospital of Changzhou (CN), Zhongda Hospital Southeast University (CN), Beijing Chest Hospital (CN), Second Affiliated Hospital of Nanchang University (CN), Nanjing Drum Tower Hospital (CN), Wuxi Fourth People's Hospital (CN), Hunan Cancer Hospital (CN), Affiliated Hospital of Qingdao University (CN), Xinqiao Hospital (CN), Qingdao Municipal Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Jilin University (CN), Shanghai Pulmonary Hospital (CN), Shanghai East Hospital (CN), Jiangsu Cancer Hospital (CN), Anhui Provincial Hospital (CN), Xuzhou Central Hospital (CN), First Hospital of Jiaxing (CN), First Hospital of China Medical University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Henan Cancer Hospital (CN), Fujian Provincial Cancer Hospital (CN), Second Affiliated Hospital of Anhui Medical University (CN), Jiangsu Province Hospital (CN), Tumor Hospital of Guangxi Medical University (CN), First Affiliated Hospital of Zhengzhou University (CN), Second People’s Hospital of Yibin (CN), Second Affiliated Hospital of Zhejiang University (CN), Zhejiang Taizhou Hospital (CN), Xiangya Hospital Central South University (CN), Shanxi Provincial People’s Hospital (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Qilu Hospital of Shandong University (CN), First Affiliated Hospital of Nanchang University (CN), University of Chinese Academy of Sciences (CN), Hangzhou Cancer Hospital (CN), Nanjing Medical University (CN), Chongqing Medical University (CN), Nanjing University (CN), China Medical University (CN), Guangzhou Medical University (CN)
Shanghai Junshi Biosciences, Science and Technology Commission of Shanghai Municipality
Good health and well-being
Openalex Percentile: Top 59%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.